Effect of Dapoxitine, Paroxetine, Combination therapy of Dapoxetine/Tadalafil and Combination therapy of Paraoxytine/Tadalafil in premature ejaculation

Comparison of the Effectiveness of Dapoxitine, Paroxetine, Combination therapy of Dapoxetine/Tadalafil and Combination therapy of Paraoxytine/Tadalafil in treatment of patients with premature ejaculation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190528043747N1

Enrollment

120

Registered

2019-11-08

Start date

2019-08-29

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ejaculation. Premature ejaculation

Interventions

Intervention 1: Control group: Paroxetine 20 mg Tablets (Tehran Shimi Company) Orally, One Tablet Daily for One Month. Intervention 2: Intervention group: Dapoxetine 30 mg Tablet (Shafa Pharmaceutical

Eligibility

Sex/Gender

Male

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Married men aged between 20 to 50 years IELT less than 2 minutes Having at least 1 sexual intercourse in a week

Exclusion criteria

Exclusion criteria: Having underlying disease including diabetes, hypertension, heart disease, thyroid disease, sexually transmitted disease, and psychiatric disease Treated with any psychiatric medication Erectile dysfunction

Design outcomes

Primary

Measure	Time frame
Cured Premature Ejaculation. Timepoint: Evaluation of Premature Ejaculation, Two and Four Weeks after Treatment. Method of measurement: Improved or not Improved Intravaginal Ejaculation Latency Time (Two Minutes) measured by the individual.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Hosseinkhani

Ardabil University of Medical Sciences

drhosseinkhani@yahoo.com+98 45 3373 3081

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026